Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype

Abstract

Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation. We found that EZH2 protein expression is induced by interleukin 6 (IL-6) in growth factor-dependent cell lines and is constitutive in IL-6-independent cell lines. Furthermore, EZH2 expression correlates with proliferation and B-cell terminal differentiation. Significantly, EZH2 protein inhibition by short interference RNA treatment results in MM cell growth arrest. Conversely, EZH2 ectopic overexpression induces growth factor independence. We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N- or K-ras gene requires EZH2 activity. Finally, this is the first report to demonstrate that EZH2 has oncogenic activity in vivo, and that cell transformation and tumor formation require histone methyltransferase activity.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Acs P, Wang QJ, Bogi K, Marquez AM, Lorenzo PS, Biro T, Szallasi Z, Mushinski JF and Blumberg PM . (1997). J. Biol. Chem., 272, 28793–28799.

  • Bajusz I, Sipos L, Gyorgypal Z, Carrington EA, Jones RS, Gausz J and Gyurkovics H . (2001). Genetics, 159, 1135–1150.

  • Billadeau D, Jelinek DF, Shah N, LeBien TW and Van Ness B . (1995). Cancer Res., 55, 3640–3646.

  • Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW and Van Ness B . (1997). Cancer Res., 57, 2268–2275.

  • Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K . (2003). EMBO J., 22, 5323–5335.

  • Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS and Zhang Y . (2002). Science, 298, 1039–1043.

  • Carrington EA and Jones RS . (1996). Development, 122, 4073–4083.

  • Chen-Kiang S . (1995). Curr. Top. Microbiol. Immunol., 194, 189–198.

  • Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM and Bergsagel PL . (1998). Blood, 92, 3025–3034.

  • Cheung WC and Van Ness B . (2001). Leukemia, 15, 264–271.

  • Cheung WC and Van Ness B . (2002). Leukemia, 16, 1182–1188.

  • Croonquist PA, Linden MA, Zhao F and Van Ness BG . (2003). Blood, 102, 2581–2592.

  • Czermin B, Melfi R, McCabe D, Seitz V, Imhof A and Pirrotta V . (2002). Cell, 111, 185–196.

  • Denisenko O, Shnyreva M, Suzuki H and Bomsztyk K . (1998). Mol. Cell. Biol., 18, 5634–5642.

  • Fukuyama T, Otsuka T, Shigematsu H, Uchida N, Arima F, Ohno Y, Iwasaki H, Fukuda T and Niho Y . (2000). Br. J. Haematol., 108, 842–847.

  • Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA and Lust JA . (1993). Cancer Res., 53, 5320–5327.

  • Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM . (2003). Proc. Natl. Acad. Sci. USA, 100, 11606–11611.

  • Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P and Reinberg D . (2002). Genes Dev., 16, 2893–2905.

  • Muller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE and Simon JA . (2002). Cell, 111, 197–208.

  • Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P and Reinberg D . (2002). Genes Dev., 16, 479–489.

  • Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P and Sharp PA . (2002). Nat. Med., 8, 681–686.

  • Raaphorst FM, Otte AP, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP and Meijer CJ . (2001). J. Immunol., 166, 5925–5934.

  • Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP and Meijer CJ . (2000). Am. J. Pathol., 157, 709–715.

  • Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD and Jenuwein T . (2000). Nature, 406, 593–599.

  • Rowley M, Liu P and Van Ness B . (2000). Blood, 96, 3175–3180.

  • Sears RC and Nevins JR . (2002). J. Biol. Chem., 277, 11617–11620.

  • Tachibana M, Sugimoto K, Fukushima T and Shinkai Y . (2001). J. Biol. Chem., 276, 25309–25317.

  • Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM . (2002). Nature, 419, 624–629.

  • Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R and Otte AP . (2001). Br. J. Haematol., 112, 950–958.

  • Wang X, Yeh S, Wu G, Hsu CL, Wang L, Chiang T, Yang Y, Guo Y and Chang C . (2001). J. Biol. Chem., 276, 40417–40423.

  • Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA and Jelinek DF . (1996). Leukemia, 10, 866–876.

  • Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B and Shaughnessy Jr J . (2002). Blood, 99, 1745–1757.

  • Zhan F, Tian E, Bumm K, Smith R, Barlogie B and Shaughnessy Jr J . (2003). Blood, 101, 1128–1140.

Download references

Acknowledgements

We thank Dr AP Otte, University of Amsterdam, The Netherlands, for providing antibodies and reagents. We also acknowledge the assistance of Dr Mesher and Dr Shimizu at the University of Minnesota in allowing the use of specific equipment. This study was supported by grants from the National Institute of Health (PO1 CA62242), from the Multiple Myeloma Research Foundation (BVN) and the National Institute of Health Cancer Biology Training Grant CA09138 (PAC).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian Van Ness.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Croonquist, P., Van Ness, B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24, 6269–6280 (2005). https://doi.org/10.1038/sj.onc.1208771

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208771

Keywords

This article is cited by

Search

Quick links